Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXCM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$79.84-0.2%$80.33$57.52▼$117.19$31.37B1.464.36 million shs5.67 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom-0.20%-3.81%-5.53%+8.55%-31.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDXCMDexCom4.8308 of 5 stars3.55.00.04.72.72.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXCMDexCom 2.95Moderate Buy$98.5023.37% UpsideCurrent Analyst Ratings BreakdownLatest DXCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025DXCMDexComTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$102.005/30/2025DXCMDexComThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$104.005/22/2025DXCMDexComCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$82.00 ➝ $102.005/5/2025DXCMDexComBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$90.00 ➝ $93.005/2/2025DXCMDexComPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$100.00 ➝ $90.005/2/2025DXCMDexComCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$103.00 ➝ $106.005/2/2025DXCMDexComRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$115.00 ➝ $105.004/10/2025DXCMDexComMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$85.004/9/2025DXCMDexComMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXCMDexCom$4.03B7.76$2.24 per share35.59$5.38 per share14.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXCMDexCom$576.20M$1.3459.5832.461.7112.90%30.05%10.00%7/24/2025 (Estimated)Latest DXCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025DXCMDexCom$0.33$0.32-$0.01$0.27$1.02 billion$1.04 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDXCMDexComN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXCMDexCom0.551.501.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXCMDexCom97.75%Insider OwnershipCompanyInsider OwnershipDXCMDexCom0.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXCMDexCom10,300392.11 million390.85 millionOptionableDXCM HeadlinesRecent News About These CompaniesIntact Investment Management Inc. Raises Holdings in DexCom, Inc. (NASDAQ:DXCM)June 23 at 4:38 AM | marketbeat.comDexcom continues advances in AI for CGM, type 2 diabetes awarenessJune 22 at 9:50 PM | drugdeliverybusiness.comDexCom (NASDAQ:DXCM) Rating Increased to Buy at Wall Street ZenJune 22 at 2:01 AM | americanbankingnews.comDexcom Ireland Announce Golfer Liam Nolan As A Brand AmbassadorJune 22 at 12:55 AM | galwaybayfm.ieDexcom shares U.S. report on CGM benefits for type 2 diabetesJune 21 at 6:33 PM | drugdeliverybusiness.comCovea Finance Sells 147,910 Shares of DexCom, Inc. (NASDAQ:DXCM)June 21 at 5:30 AM | marketbeat.comDexCom (NASDAQ:DXCM) Raised to Buy at Wall Street ZenJune 21 at 2:34 AM | marketbeat.comDXCM's Access Gains and Operational Strength Offset Margin PressuresJune 20, 2025 | zacks.comSilver Oak Securities Incorporated Invests $456,000 in DexCom, Inc. (NASDAQ:DXCM)June 20, 2025 | marketbeat.comDexCom, Inc. (NASDAQ:DXCM) Shares Acquired by QRG Capital Management Inc.June 20, 2025 | marketbeat.comInsider Selling: DexCom, Inc. (NASDAQ:DXCM) EVP Sells 500 Shares of StockJune 19, 2025 | insidertrades.comJanney Montgomery Scott LLC Acquires 5,881 Shares of DexCom, Inc. (NASDAQ:DXCM)June 19, 2025 | marketbeat.comQ1 Rundown: DexCom (NASDAQ:DXCM) Vs Other Patient Monitoring StocksJune 18, 2025 | finance.yahoo.comInsider Selling: DexCom, Inc. (NASDAQ:DXCM) EVP Sells 500 Shares of StockJune 18, 2025 | marketbeat.comMark G. Foletta Sells 2,750 Shares of DexCom, Inc. (NASDAQ:DXCM) StockJune 18, 2025 | marketbeat.comDexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025June 18, 2025 | businesswire.comDexCom, Inc. (NASDAQ:DXCM) Director Sells $213,864.42 in StockJune 18, 2025 | insidertrades.comSagespring Wealth Partners LLC Acquires 5,172 Shares of DexCom, Inc. (NASDAQ:DXCM)June 18, 2025 | marketbeat.comDexCom Stock: Is DXCM Underperforming the Health Care Sector?June 17, 2025 | theglobeandmail.comInsider Selling: DexCom, Inc. (NASDAQ:DXCM) Director Sells 2,618 Shares of StockJune 17, 2025 | marketbeat.comDexCom, Inc. (NASDAQ:DXCM) Director Nicholas Augustinos Sells 3,672 SharesJune 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDXCM Company DescriptionsDexCom NASDAQ:DXCM$79.84 -0.16 (-0.20%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$80.98 +1.15 (+1.43%) As of 06/23/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
